18 results
S-3ASR
EX-4.3
IMNM
Immunome, Inc.
13 Feb 24
Automatic shelf registration
4:04pm
commenced hereunder shall initially bear such Party’s own costs and expenses (including expert witness and attorneys’ fees) of investigating, preparing
8-K
EX-2.1
IMNM
Immunome, Inc.
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
application submitted to the applicable Regulatory Authority, including any amendments thereto.
“Independent Expert” has the meaning set forth … (such agreed firm, the “Independent Expert”). The Independent Expert’s determination of Net Sales shall be within the range of values proposed
8-K
IMNM
Immunome, Inc.
4 Oct 23
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
6:56am
. Turner served in roles of increasing responsibility at Hoffman-La Roche, most recently as Expert Scientist from 2013 to 2017. Dr. Turner received
S-4
EX-10.49
c93ub
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
PRE 14A
88s568ky5v4usl f791
7 Apr 23
Preliminary proxy
6:29am
8-K
EX-99.1
lcjdjeexe9s0f6vwh
8 Feb 22
Other Events
8:27am
8-K
EX-99.1
wd4uiy9qo861mwo4b
18 Oct 21
Regulation FD Disclosure
4:27pm
8-K
EX-99.1
vwk34
21 Sep 21
Regulation FD Disclosure
7:40am
DEF 14A
u4f 4i32l2
16 Apr 21
Definitive proxy
3:35pm
424B4
k19zr5t
5 Oct 20
Prospectus supplement with pricing info
5:10pm
S-1/A
qsimgu4bcscgkz8mte
24 Sep 20
IPO registration (amended)
7:18am
S-1
uxt45y f7gn8juj7zgv9
9 Sep 20
IPO registration
4:19pm
S-1
EX-10.1
wzgsh f698o7fejy8p4
9 Sep 20
IPO registration
4:19pm
DRS
3mqdo
12 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next